LUX-lung 3: A randomized, open-label, phase III study of afatinib vs pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations

Lung Cancer ◽  
2012 ◽  
Vol 77 ◽  
pp. S25-S26 ◽  
Author(s):  
Martin Schuler ◽  
James Chih-Hsin Yang ◽  
Nobuyuki Yamamoto ◽  
Ken O’Byrne ◽  
Vera Hirsh ◽  
...  
Keyword(s):  
Phase Iii ◽  
Line Treatment ◽  
First Line ◽  
Open Label ◽  
Activating Mutations ◽  
Adenocarcinoma Of The Lung ◽  
Open Label Phase ◽  
Phase Iii Study ◽  
First Line Treatment

LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. LBA7500-LBA7500 ◽  
Author(s):  
James Chih-Hsin Yang ◽  
Martin H. Schuler ◽  
Nobuyuki Yamamoto ◽  
Kenneth John O'Byrne ◽  
Vera Hirsh ◽  
...  
Keyword(s):  
Phase Iii ◽  
First Line ◽  
Open Label ◽  
Daily News ◽  
Activating Mutations ◽  
Adenocarcinoma Of The Lung ◽  
Open Label Phase ◽  
Phase Iii Study ◽  
Final Text ◽  
First Line Treatment

LBA7500 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Sign in / Sign up

Export Citation Format

Share Document